Evidence map›Paper›PMID 29346371›Full record

ArticlePLoS neglected tropical diseases2018

Identification of novel leishmanicidal molecules by virtual and biochemical screenings targeting Leishmania eukaryotic translation initiation factor 4A.

Emna Harigua-Souiai, Yosser Zina Abdelkrim, Imen Bassoumi-Jamoussi, Ons Zakraoui, Guillaume Bouvier, Khadija Essafi-Benkhadir, Josette Banroques, Nathan Desdouits, Hélène Munier-Lehmann, Mourad Barhoumi and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Article
  3. Repurposing approved drugs targetingFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Article
  6. Approved drugs successfully repurposed againstFrontiers in cellular and infection microbiology · 2024
    Article
  7. Enzymatic and Molecular Characterization of Anti-Molecules (Basel, Switzerland) · 2022
    Article
  8. TheGenes · 2021
    Article
  9. Article
  10. Article
  11. Review
  12. Infection of Human Neutrophils WithFrontiers in cellular and infection microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Emna Harigua-SouiaiLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Yosser Zina AbdelkrimLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Imen Bassoumi-JamoussiLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Ons ZakraouiLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Guillaume BouvierInstitut Pasteur, Unité de Bioinformatique Structurale, CNRS UMR 3528, Département de Biologie Structurale et Chimie, Paris, France.
Khadija Essafi-BenkhadirLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Josette BanroquesLaboratory of Microbial Gene Expression (EGM), CNRS UMR8261/Université Paris Diderot P7, Sorbonne Paris Cité & PSL, Institut de Biologie Physico-Chimique, Paris, France.
Nathan DesdouitsInstitut Pasteur, Unité de Bioinformatique Structurale, CNRS UMR 3528, Département de Biologie Structurale et Chimie, Paris, France.
Hélène Munier-LehmannInstitut Pasteur, Unité de Chimie et Biocatalyse, Département de Biologie Structurale et Chimie, Paris, France.
Mourad BarhoumiLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
N Kyle TannerLaboratory of Microbial Gene Expression (EGM), CNRS UMR8261/Université Paris Diderot P7, Sorbonne Paris Cité & PSL, Institut de Biologie Physico-Chimique, Paris, France.
Michael NilgesInstitut Pasteur, Unité de Bioinformatique Structurale, CNRS UMR 3528, Département de Biologie Structurale et Chimie, Paris, France.
Arnaud BlondelInstitut Pasteur, Unité de Bioinformatique Structurale, CNRS UMR 3528, Département de Biologie Structurale et Chimie, Paris, France.
Ikram GuizaniLaboratory of Molecular Epidemiology and Experimental Pathology - LR11IPT04, Institut Pasteur de Tunis, Université de Tunis el Manar, Tunis, Tunisia.
Institut Pasteur · FRTunis University · TNTunis El Manar University · TNCentre National de la Recherche Scientifique · FRExpression Génétique Microbienne · FRInstitut de Biologie Physico-Chimique · FRInstitut Pasteur de Tunis · TNUniversity of Carthage · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniases are neglected parasitic diseases in spite of the major burden they inflict on public health. The identification of novel drugs and targets constitutes a research priority. For that purpose we used Leishmania infantum initiation factor 4A (LieIF), an essential translation initiation factor that belongs to the DEAD-box proteins family, as a potential drug target. We modeled its structure and identified two potential binding sites. A virtual screening of a diverse chemical library was performed for both sites. The results were analyzed with an in-house version of the Self-Organizing Maps algorithm combined with multiple filters, which led to the selection of 305 molecules. Effects of these molecules on the ATPase activity of LieIF permitted the identification of a promising hit (208) having a half maximal inhibitory concentration (IC50) of 150 ± 15 μM for 1 μM of protein. Ten chemical analogues of compound 208 were identified and two additional inhibitors were selected (20 and 48). These compounds inhibited the mammalian eIF4I with IC50 values within the same range. All three hits affected the viability of the extra-cellular form of L. infantum parasites with IC50 values at low micromolar concentrations. These molecules showed non-significant toxicity toward THP-1 macrophages. Furthermore, their anti-leishmanial activity was validated with experimental assays on L. infantum intramacrophage amastigotes showing IC50 values lower than 4.2 μM. Selected compounds exhibited selectivity indexes between 19 to 38, which reflects their potential as promising anti-Leishmania molecules.

Indexed as

Adenosine TriphosphatasesAntiprotozoal AgentsBinding SitesDrug Evaluation, PreclinicalEukaryotic Initiation Factor-4AInhibitory Concentration 50Leishmania infantumModels, MolecularMolecular Docking SimulationParasitic Sensitivity TestsAdenosine TriphosphatasesAntiprotozoal AgentsEukaryotic Initiation Factor-4A

Identifiers

PMID29346371
PMCPMC5790279
OpenAlexW2784028025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.